The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...
The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Lantus (insulin glargine) and a possible increased risk of cancer. Lantus is a long-acting ...
Of the more than 30 million Americans with diabetes, about 7.4 million use one or more forms of supplemental insulin to help keep their blood sugar levels within a certain target range. Insulin ...
The dosage of Lantus is individualized and depends on several factors, such as the type of diabetes being treated, your body weight, blood sugar goals, and response to treatment. Lantus is given as a ...
GoodRx announced Thursday morning that it is working with Sanofi on a program to offer one of its leading insulin products to consumers for $35 per month. By visiting ...
In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went ...
This Interchangeable Biosimilar Insulin Glargine Approved for U.S. Distribution Through Newly Established Subsidiary Lanexa Biologics LLC Lannett Company, Inc., Lanexa Biologics, a wholly owned ...
Technically, there is no official “generic” insulin. However, several newer unbranded insulins have been introduced in recent years. These are both fast-acting bolus insulin and long-acting basal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results